maytansine

Maytansine (NSC-153858) 是从变叶美登木中分离的一种高效微管靶向天然产物，可诱导有丝分裂阻滞并在亚纳摩尔浓度杀死肿瘤细胞。

Maytansine derivative M24 是一种ADC药物-连接子偶联物(Drug-Linker Conjugates for ADC)，用于合成ADC [REGN5093-M114]。

Val-Cit-amide-Ph-Maytansine 是用于肝细胞生长因子受体 c-Met (MET) 或抗体药物偶联物 (ADCs) 的抗体和双特异性抗原结合分子。

Val-Cit-amide-Cbz-N(Me)-Maytansine是一种可用于构建抗体和双特异性抗原结合分子，能够特异性结合肝细胞生长因子受体c-Met (MET)以及用于制备抗体药物偶联物(antibody-drug conjugates) (ADCs)的化合物。

DM3-SMe is a maytansine derivative and tubulin inhibitor. It is a cytotoxic part of antibody-drug conjugates (ADCs) and can bind to antibodies via disulfide bonds or stable thioether bonds. DM3-SMe has high cytotoxic activity in vitro with IC50 of 0.0011

DM3 (Maytansinoid DM3) is a maytansine mimic with disulfide or thiol groups, acting as a tubulin inhibitor and serving as the cytotoxic component in antibody-drug conjugates (ADCs).

S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin(Kd of 0.93 μM) and inhibts microtubule polymerization.

Maytansinoid DM4, a thiol-containing maytansine derivative, is a highly potent cytotoxic moiety utilized in ADC applications.

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid.

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

DM1-SMe (DM1-SSMe) 是美登木素微管的有效抑制剂。 DM1-SMe 的效力是母体药物美登素的 3 至 10 倍，在一组人类肿瘤细胞系中，DM1-SMe 的 IC50 为 0.003 至 0.01 nM。

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine. This compound is utilized in the investigation of advanced breast cancer[1][2].

Cantuzumab mertansine (SB-408075; huC242-DM1) 是一种ADC，是强效美登素衍生物 (DM1) 和针对 CanAg 的人源化单克隆抗体 (huC242) 的免疫偶联物。Cantuzumab mertansine 对结肠癌细胞具有细胞毒性，并且对一系列 CanAg 阳性人肿瘤异种移植物具有广泛的抗肿瘤活性。